Literature DB >> 15984894

Rapid cycling bipolar disorder: clinical characteristics and treatment options.

William Coryell1.   

Abstract

Approximately one of six patients who seek treatment for bipolar disorder present with a rapid cycling pattern. In comparison with other patients who have bipolar disorder, these individuals experience more affective morbidity in both the immediate and distant future and are more likely to experience recurrences despite treatment with lithium or anticonvulsants. Particular care should be given to distinguishing rapid cycling bipolar disorder from attention-deficit hyperactivity disorder in children or adolescents and from borderline personality disorder in adults. Perhaps four of five cases of rapid cycling resolve within a year, but the pattern may persist for many years in the remaining patients. As with bipolar disorder in general, depressive symptoms produce the most morbidity over time. Controlled studies have not established that antidepressants provoke switching or rapid cycling, but neither have they been shown consistently to have benefits in bipolar illness. Successful management will often require a sequence of trials with mood stabilizer drugs, beginning with lithium in treatment-naive patients. Efforts to minimise adverse effects, and the recognition that full benefits may not be apparent for several months, will make the premature abandonment of a potentially helpful treatment less likely. Placebo-controlled studies so far provide the most support for the use of lithium and lamotrigine as prophylactic agents. The combination of lithium and carbamazepine, valproate or lamotrigine for maintenance has some support from controlled studies, as does the adjunctive use of olanzapine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15984894     DOI: 10.2165/00023210-200519070-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  100 in total

1.  A double-blind comparison of valproate and lithium in the treatment of acute mania.

Authors:  T W Freeman; J L Clothier; P Pazzaglia; M D Lesem; A C Swann
Journal:  Am J Psychiatry       Date:  1992-01       Impact factor: 18.112

2.  Lithium response and the sequence of episode polarities: preliminary report on a Hamilton sample.

Authors:  E Grof; M Haag; P Grof; H Haag
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1987       Impact factor: 5.067

3.  Long-term prognosis of bipolar I disorder.

Authors:  C L Turvey; W H Coryell; D A Solomon; A C Leon; J Endicott; M B Keller; H Akiskal
Journal:  Acta Psychiatr Scand       Date:  1999-02       Impact factor: 6.392

4.  Sequence of affective polarity and lithium response: preliminary report on Munich sample.

Authors:  H Haag; A Heidorn; M Haag; W Greil
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1987       Impact factor: 5.067

Review 5.  A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder.

Authors:  Robert M A Hirschfeld; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2004-09-30       Impact factor: 5.176

6.  Clinical features related to age at onset in bipolar disorder.

Authors:  Carrie L Ernst; Joseph F Goldberg
Journal:  J Affect Disord       Date:  2004-10-01       Impact factor: 4.839

7.  Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison.

Authors:  J M Kane; F M Quitkin; A Rifkin; J R Ramos-Lorenzi; D D Nayak; A Howard
Journal:  Arch Gen Psychiatry       Date:  1982-09

8.  A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness.

Authors:  T Okuma; K Inanaga; S Otsuki; K Sarai; R Takahashi; H Hazama; A Mori; S Watanabe
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; Kenneth R Silk
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

10.  Relation of serum valproate concentration to response in mania.

Authors:  C L Bowden; P G Janicak; P Orsulak; A C Swann; J M Davis; J R Calabrese; P Goodnick; J G Small; A J Rush; S E Kimmel; S C Risch; D D Morris
Journal:  Am J Psychiatry       Date:  1996-06       Impact factor: 18.112

View more
  6 in total

Review 1.  Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations.

Authors:  Gin S Malhi; Michelle Tanious
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 2.  Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches.

Authors:  Martin Begemann; Derya Sargin; Moritz J Rossner; Claudia Bartels; Fabian Theis; Sven P Wichert; Nike Stender; Benjamin Fischer; Swetlana Sperling; Sabina Stawicki; Anne Wiedl; Peter Falkai; Klaus-Armin Nave; Hannelore Ehrenreich
Journal:  Mol Med       Date:  2008 Sep-Oct       Impact factor: 6.354

Review 4.  Pharmacological treatment of bipolar disorder among children and adolescents.

Authors:  Joseph C Blader; Vivian Kafantaris
Journal:  Expert Rev Neurother       Date:  2007-03       Impact factor: 4.618

5.  Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.

Authors:  Wayne Macfadden; Caleb M Adler; Ibrahim Turkoz; John T Haskins; Norris Turner; Larry Alphs
Journal:  BMC Psychiatry       Date:  2011-10-28       Impact factor: 3.630

Review 6.  Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations.

Authors:  Paolo Girardi; Roberto Brugnoli; Giovanni Manfredi; Gabriele Sani
Journal:  Drugs R D       Date:  2016-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.